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Abstract We examined the effect of methionine oxidation of
human recombinant K-synuclein on its structural properties
and propensity to fibrillate. Both oxidized and non-oxidized
K-synucleins were natively unfolded under conditions of neutral
pH, with the oxidized protein being slightly more disordered.
Both proteins adopted identical partially folded conformations
under conditions of acidic pH. The fibrillation of K-synuclein at
neutral pH was completely inhibited by methionine oxidation.
This inhibitory effect was eliminated at low pH. The addition of
oxidized K-synuclein to the unoxidized form led to a substantial
inhibition of K-synuclein fibrillation. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Although oxygen is important for life, under certain con-
ditions it can give rise to a number of highly reactive and,
thus, potentially toxic species. Under normal conditions, cells
are able to eliminate reactive oxygen species (ROS) by anti-
oxidants, metal chelators or enzymatic reduction. However,
when the level of ROS exceeds its defense mechanisms, the
cell may su¡er from the oxidative stress. Organisms have
evolved complex antioxidant defenses to minimize oxidative
damage to proteins and other macromolecules. They also pos-
sess repair systems for reversing some oxidative modi¢cations
and disposal systems for removing modi¢ed macromolecules,
which are not repaired.
All amino acids are susceptible to oxidation, although their
susceptibilities vary greatly [1]. It is known that methionine is
one of the most readily oxidized amino acid constituents of
proteins. It is easily oxidized to methionine sulfoxide, MetO,
by H2O2, hydroxyl radicals, hypochlorite, chloramines, and
peroxynitrite; all these oxidants are produced in biological
systems [2]. However, this modi¢cation can be repaired by
MetO reductase (MSR), which catalyzes the thioredoxin-de-
pendent reduction of MetO back to methionine [3,4]. Based
on these observations it is assumed that oxidation of surface-
exposed methionines may serve to protect other functionally
essential residues from oxidative damage [5].
Oxidation-modi¢ed proteins accumulate during normal
aging [6^8], and oxidative injury is implicated in the patho-
genesis of several disorders including Alzheimer’s disease
(AD) [9], Parkinson’s disease (PD) [10], dementia with Lewy
bodies (LBs) [11], amyotrophic lateral sclerosis [12], Hunting-
ton’s disease [13], in£ammatory diseases [14], cataractogenesis
[14], atherosclerosis [15], brain ischemia and carcinogenesis
[16].
PD is the second most common neurodegenerative disorder
(after AD) that a¡ects approximately 1% of the population
over age 60. PD symptoms are attributed to the progressive
loss of dopaminergic neurons from the substantia nigra region
of brain. Some surviving nigral dopaminergic neurons contain
cytosolic ¢lamentous inclusions known as LBs and Lewy neu-
rites (LNs) [17,18]. Several observations have implicated the
presynaptic protein K-synuclein in the pathogenesis of PD.
K-Synuclein was shown to be a major ¢brillar component of
LBs and LNs [19], and the missense mutations A53T and
A30P in K-synuclein have been identi¢ed in a small number
of kindreds with autosomal-dominantly inherited, early-onset
PD [20,21]. Finally, the production of K-synuclein in trans-
genic mice [22] or in transgenic £ies [23] leads to the motor
de¢cits and neuronal inclusions reminiscent of PD.
K-Synuclein is a small (14 kDa), highly conserved presyn-
aptic protein that is abundant in various regions of the brain
[24]. It has four methionines, Met1, Met5, Met116 and
Met127, located outside the repeat-containing region. Struc-
turally, puri¢ed K-synuclein belongs to the rapidly growing
family of natively unfolded proteins [25^35], which have little
or no ordered structure under physiological conditions, due to
a unique combination of low overall hydrophobicity and large
net charge [36]. In vitro, the protein forms ¢brils with mor-
phologies and staining characteristics similar to those ex-
tracted from disease-a¡ected brain [37^42].
Oxidative injury has been implicated in the pathogenesis of
PD [10,43]. The existence of extensive and widespread accu-
mulation of nitrated K-synuclein (i.e. protein containing the
product of the tyrosine oxidation, 3-nitrotyrosine) in the sig-
nature inclusions of PD brains has been demonstrated [10,43].
Accumulation of another product of tyrosine oxidation, dity-
rosine, has been detected in vitro during experiments on the
aggregation of K-synuclein in the presence of copper and
H2O2 [44] or catecholamines [45]. Despite these reports, noth-
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ing is currently known about the e¡ect of methionine oxida-
tion on the structural and ¢brillation properties of K-synu-
clein. In this report, we describe the e¡ect of methionine ox-
idation to the sulfoxide on the structural and ¢brillation
properties of human recombinant K-synuclein in vitro.
2. Materials and methods
2.1. Expression and puri¢cation of human K-synuclein
Human wild-type (WT) K-synuclein was expressed in the Escheri-
chia coli BL21(DE3) cell line transfected with pRK172/K-synuclein
WT plasmid (kind gift of M. Goedert, MRC Cambridge) and puri¢ed
by a procedure described by Conway et al. [37].
2.2. Supplies and chemicals
Thio£avine T (TFT) was obtained from Sigma, St. Louis, MO,
USA. All other chemicals were of analytical grade from Fisher Chem-
icals.
2.3. Oxidation of K-synuclein by hydrogen peroxide
Oxidation of K-synuclein was induced by the incubation of protein
solution (3.12 mg/ml in 25 mM sodium phosphate bu¡er, 100 mM
NaCl, pH 8.0) in the presence of 4% H2O2 for 20 min. Non-reacted
peroxide was removed from the protein solution by ultra¢ltration
(10 000 molecular weight cuto¡, Microcon (Amicon)) at 7000 rpm
for 2 h. Success of oxidation was con¢rmed by mass spectrometry
(MS) analysis (MicroMass Quattro II). Samples for MS analysis
were prepared by diluting 2 Wl of protein solution in 200 Wl of 50%
acetonitrile/50% pH 2.0 HCl mixture.
2.4. Circular dichroism (CD) measurements
CD spectra were obtained on an AVIV 60DS spectrophotometer
(Lakewood, NJ, USA) using K-synuclein concentrations of 1.0 mg/ml.
Spectra were recorded in 0.01 cm cells from 250 to 190 nm with a step
size of 1.0 nm, with a bandwidth of 1.5 nm, and an averaging time of
10 s. For all spectra, an average of ¢ve scans was obtained. CD
spectra of the appropriate bu¡ers were recorded and subtracted
from the protein spectra.
2.5. Fourier transform infrared (FTIR) spectra
Data were collected on a Nicolet 800SX FTIR spectrometer
equipped with an MCT detector. The IRE (72U10U6 mm, 45‡ ger-
manium trapezoid) was held in a modi¢ed SPECAC out-of-compart-
ment ATR apparatus. The hydrated thin ¢lms were prepared and
analyzed as described previously [46].
2.6. Fibril formation assay
Fibril formation of oxidized and non-oxidized K-synuclein at pH
3.0 and 7.5 (20 mM Na-phosphate bu¡er, 100 mM NaCl) was moni-
tored in a £uorescence plate reader (Fluoroskan Ascent). Protein so-
lutions contained 20 WM TFT and protein at a concentration of 1.0
mg/ml (70 WM) in the corresponding ¢brillation bu¡er. A volume of
145 Wl of the mixture was pipetted into a well of a 96-well plate (white
plastic, clear bottom) and a 1/8 inch diameter Te£on sphere (McMas-
ter-Carr, Los Angeles, CA, USA) was added. Each sample was run in
triplicate or quadruplicate. The plate was loaded into a £uorescence
plate reader and incubated at 37‡C with shaking at 150 rpm with a
shaking diameter of 20 mm. The £uorescence was measured at 30 min
intervals with excitation at 450 nm and emission at 485 nm, and curve
¢t as described in [47].
3. Results and discussion
3.1. In vitro oxidative modi¢cation of human K-synuclein
MS analysis of K-synuclein prior to the oxidative modi¢ca-
tion revealed one major peak, whose molecular mass was
centered at 14 460 þ 3 Da, which coincides with the molecular
mass of human K-synuclein calculated from its amino acid
sequence (14 460.09 Da). The conditions used for the in vitro
oxidative modi¢cation of K-synuclein result in oxidation of all
four methionines, as it was evidenced by the MS major peak
positioned at 14 524 þ 3 Da that corresponds to the mass
of human K-synuclein plus four oxygens (i.e. 14 460.09
Da+16.00U4 Da = 14 524.09 Da).
3.2. E¡ect of methionine oxidation on secondary structure of
human K-synuclein
Fig. 1 shows the FTIR (amide I region) spectra measured
for non-oxidized (A) and oxidized forms (B) of human re-
combinant K-synuclein at pH 7.5. The FTIR spectra of both
proteins are typical of a substantially unfolded polypeptide
chain. The results of the deconvolution (FSD and second de-
rivative) of the FTIR spectra are summarized in Table 1 and
show that K-synuclein-MetO contains smaller amounts of
L-structure under these conditions. We attribute the increased
degree of unfolding of the oxidized protein to the decreased
hydrophobicity of oxidized methionine [2] leading to a de-
crease in the overall hydrophobicity of the protein. In fact,
in contrast to the cysteine oxidation, which will change the
charge on the protein, the conversion of Met to MetO is
expected to modify the polarity and hydrophobicity of poly-
peptide chain, but not its charge [2]. Moreover, the formation
of MetO was even regarded as a chemical ‘mutagenesis’,
which substitutes the hydrophobic and £exible side chain of
methionine with MetO, a larger, more polar and less £exible
side chain [48]. Interestingly, it has recently been reported that
another member of the synuclein family, L-synuclein, which
lacks the 11 residues of the central hydrophobic region of
K-synuclein, also has the properties expected of a random
coil, whereas some residual structure was detected in
K-synuclein [49]. Thus, a decrease in the overall hydrophobic-
ity in both L-synuclein and K-synuclein-MetO leads to a more
disordered conformation, compared to K-synuclein.
Fig. 1. Secondary structure analysis of non-oxidized (A) and oxi-
dized K-synuclein (B) by FTIR. FTIR spectra of the amide I region
were measured at pH 7.5 (solid line). Curve ¢t spectra are present
by dotted lines.
FEBS 26027 12-4-02
V.N. Uversky et al./FEBS Letters 517 (2002) 239^244240
In agreement with FTIR data, the far-UV CD spectrum
of K-synuclein-MetO measured at pH 7.5 shows a slightly
increased degree of disorder in comparison with the non-
oxidized protein (Fig. 2). This is manifested by a small in-
crease in negative ellipticity in the vicinity of 196 nm and
somewhat lower intensity in the vicinity of 222 nm. As the
pH is decreased, a decrease in the minimum at 196 nm is
accompanied by an increase in negative intensity around 222
nm, re£ecting pH-induced formation of secondary structure
(Fig. 2). Importantly, non-oxidized and oxidized proteins pos-
sess almost identical far-UV CD spectra at acidic pH. More-
over, the pH-induced changes in the far-UV CD spectra of
both forms of K-synuclein were completely reversible. Previ-
ously we have shown that the pH-induced increase in struc-
ture in members of the synuclein family represents an intra-
molecular process involving the formation of a partially
folded intermediate, and not self-association [26,40,49].
Thus, this also appears to be the situation for the MetO
form of human K-synuclein.
3.3. The e¡ect of methionine oxidation on the ¢brillation
of K-synuclein
TFT is a £uorescent dye that interacts with amyloid ¢brils
leading to an increase in the £uorescence intensity in the vi-
cinity of 480 nm [50]. Fig. 3 compares ¢brillation patterns of
non-oxidized and oxidized K-synuclein monitored by TFT
£uorescence. Fibril formation for the non-oxidized K-synu-
clein at neutral pH is characterized by a typical sigmoidal
curve. In contrast, there was no evidence of ¢bril formation
by methionine-oxidized K-synuclein at neutral pH on the time-
scale shown. In fact, ¢brils were not formed even after incu-
bation of K-synuclein-MetO for 300 h.
In agreement with earlier studies [26,49], acidi¢cation of
non-oxidized K-synuclein solution leads to signi¢cant acceler-
ation of the ¢bril formation process (Fig. 3). This is attributed
to the pH-induced stabilization of a partially folded inter-
mediate, which represents a crucial primary step in the
K-synuclein ¢brillation pathway [26]. Fig. 3 shows that the
non-oxidized and oxidized forms of K-synuclein ¢brillate sim-
ilarly under conditions of low pH. This means that the inhib-
itory e¡ect of methionine oxidation is eliminated under con-
ditions of low pH, which favor formation of a partially folded
intermediate in both forms of the protein.
3.4. Aggregation of non-oxidized and oxidized K-synucleins
In the presence of methanol, K-synuclein undergoes a con-
formational change and self-associates to form soluble oligo-
mers, enriched with L-structure, which aggregate and form
insoluble precipitates at higher protein and methanol concen-
trations [40]. Consequently, neutral pH methanol solutions
represent suitable conditions to study the propensity of
K-synuclein to aggregate. We have established that in contrast
to the non-oxidized protein, K-synuclein-MetO does not form
insoluble aggregates in 80% methanol and high protein con-
centrations. In fact, there was no light scattering in the solu-
tion of the K-synuclein-MetO even when the protein concen-
tration was as high as 3 mg/ml (data not shown). Thus, our
Table 1
Secondary structure analysis of non-oxidized and oxidized forms of human K-synuclein, determined by FTIR
Structural assignment K-Synuclein, non-oxidized K-Synuclein, oxidized
Wavenumber (cm31) % Wavenumber (cm31) %
Turn or L-sheet 1692 1.4 þ 0.1 1691 1.6 þ 0.1
Turn 1680 12.7 þ 0.9 1678 12.4 þ 0.9
Loops 1664 16.4 þ 1.1 1663 22.1 þ 1.5
Disordered 1651 27.1 þ 1.9 1649 31.5 þ 2.2
L-Sheet 1637 28.7 þ 2.0 1636 26.1 þ 1.9
L-Sheet 1627 13.8 þ 1.0 1625 6.3 þ 0.5
The estimated error in the frequencies is þ 1.5 cm31.
Fig. 2. Comparison of the e¡ect of pH on far-UV CD spectra of
non-oxidized (solid lines) and oxidized K-synuclein (dashed lines).
Far-UV CD spectra were measured at pH 7.5 and pH 3.0 (20 mM
Na-phosphate bu¡er, 100 mM NaCl). For far-UV CD measure-
ments the cell pathlength was 0.1 mm. Measurements were carried
out at 23‡C. Protein concentration was 0.5 mg/ml.
Fig. 3. Kinetics of ¢brillation of non-oxidized (open symbols) and
oxidized (gray symbols) K-synuclein monitored by the enhancement
of TFT £uorescence intensity. Measurements were performed at
37‡C and pH 7.5 (circles) or pH 3.0 (triangles) in 20 mM Na-phos-
phate bu¡er containing 100 mM NaCl. ThT £uorescence was ex-
cited at 450 nm, and the emission wavelength was 482 nm.
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data are consistent with the conclusion that the propensity of
K-synuclein to aggregate is signi¢cantly diminished by the
methionine oxidation. Similar MetO-induced inhibition of ag-
gregation has been reported earlier for AL(1^40) [51].
3.5. K-Synuclein-MetO inhibits ¢brillation of the
non-oxidized protein
Fig. 4 represents an intriguing set of data on the e¡ect of
oxidized K-synuclein on the ¢brillation kinetics of the non-
oxidized protein. The addition of oxidized protein in a two-
fold molar excess to 70 WM solution of non-oxidized K-synu-
clein substantially increased the duration of the lag time, but
had little e¡ect on the rate constant for ¢bril growth (Fig. 4).
Further increase in the relative concentration of the oxidized
protein (4:1 molar excess of K-synuclein-MetO over the non-
oxidized K-synuclein) led to almost complete inhibition of the
non-oxidized protein ¢brillation (Fig. 4). These results suggest
that a non-productive interaction between oxidized and non-
oxidized forms of human K-synuclein inhibits the formation
of nuclei, rather than growth of nascent ¢brils. Similar mutual
inhibition with respect to nucleation, but not to ¢bril elonga-
tion, has been reported for several other pairs of homologous
proteins. Examples include non-¢brillogenic Q-chain/¢brillo-
genic mutant L-chain of hemoglobin in sickle cell disease
[52]; AL40/AL42 in Alzheimer’s L-amyloid ¢bril formation
[53]; mouse/WT human and mouse/A53T human K-synucleins
[54]; human L/K- and Q/K-synucleins [49]. Importantly, it has
been reported that inhibition of mouse K-synuclein ¢brillation
by human WT and A53T proteins leads to the accumulation
of non-¢brillar spherical oligomers [54]. We assume that the
inhibition of ¢bril formation by non-oxidized K-synuclein in
the presence of oxidized protein also originates from the ef-
fective formation of soluble hetero-oligomers, which are lo-
cated o¡ the ¢brillation pathway.
Models for the aggregation of non-oxidized (A) and oxi-
dized (B) K-synuclein at neutral pH are shown in Fig. 5. The
model for aggregation of both forms of the protein at acidic
pH is also shown for comparison (Fig. 5C). In the model O, F
and A represent soluble oligomers, ¢brils and amorphous ag-
gregates, respectively; UN and UN are the natively unfolded
states of non-oxidized and oxidized K-synuclein, respectively;
and I represents the partially folded intermediate. The Roman
numerals indicate the major stages of the aggregation process.
Taking into account the observations presented in the current
study, we propose that methionine oxidation leads to a de-
crease in K-synuclein residual structure (UN vs. UN ), due to
the oxidation-induced increase in the overall polarity of the
protein. This leads to a shift in the equilibrium in stage I for
the oxidized protein, UNHI, in favor of the unfolded con-
formation UN. Finally, stages II, III and V are arrested (or at
least strongly inhibited) by the oxidation at neutral pH, but
formation of soluble oligomers still occurs, stage IV (Fig. 5B).
Both forms of K-synuclein show similar aggregation behavior
at acidic pH (Fig. 5C). Here non-oxidized and oxidized forms
of K-synuclein are more prone to form the partially folded
conformation (thicker arrow at stage I) and, as a conse-
quence, show a faster rate of aggregation (stages II^V).
A model for the inhibitory e¡ect of oxidized K-synuclein on
the non-oxidized protein ¢brillation is shown in Fig. 6. In the
mixture of non-oxidized and oxidized proteins the conforma-
tional equilibrium is shifted toward the formation of soluble
hetero-oligomers.
Giving the prevailing view [10,43] that oxidative stress is a
key factor in the etiology of PD, our data on the e¡ect of
methionine oxidation are interesting. We have shown that
methionine-oxidized K-synuclein, which is expected to repre-
sent one of the most common products of oxidative damage
to K-synuclein, fails to form ¢brils at neutral pH. Moreover,
¢brillation of non-oxidized K-synuclein is inhibited in the
presence of an excess of methionine-oxidized K-synuclein. As
Fig. 4. Inhibition of ¢brillation of non-oxidized K-synuclein in the
presence of oxidized K-synuclein. The ¢brillation kinetics were
studied for 70 WM non-oxidized K-synuclein solution in 20 mM Na-
phosphate bu¡er, 100 mM NaCl, pH 7.5 in the absence (1) or pres-
ence of oxidized protein in a 1:2 (3), and 1:4 molar ratio (4). Fibril-
lation kinetics of the oxidized proteins are shown for comparison
(2).
Fig. 5. Models of non-oxidized and oxidized K-synuclein aggrega-
tion under the di¡erent experimental conditions (see the text for ex-
planations). A: Aggregation of the non-oxidized protein at neutral
pH. B: Aggregation of the oxidized protein at neutral pH. C: Ag-
gregation of non-oxidized and oxidized proteins at acidic pH.
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noted, oxidized methionine can be repaired by MSR, which
catalyzes the thioredoxin-dependent reduction of MetO back
to methionine [3^5]. Based on this observation it was assumed
that reversible oxidation of methionines might protect other
functionally essential residues from oxidative damage [5]. The
e⁄ciency of such protection in case of K-synuclein may be
signi¢cant, since the concentration of K-synuclein is high
(this protein has been estimated to account for as much as
1% of the total protein in soluble cytosolic brain fractions
[55]). Moreover, it has been shown recently that exposure of
mice to the herbicide paraquat causes upregulation of K-syn-
uclein, giving rise to the idea that increased expression of
K-synuclein is a part of a neuronal response to toxic insult
[56]. This observation, together with the potential protective
role of methionine, leads to an intriguing hypothesis that
K-synuclein may be used by the cells as a natural scavenger
of ROS. This may keep K-synuclein from irreversible over-
oxidation, but at the same time may protect any oxidizable
proteins present in the K-synuclein microenvironment, and
may also protect against lipid oxidation. Most importantly,
the proposed K-synuclein scavenging system, which may pro-
tect K-synuclein from over-oxidation, is dependent upon the
e¡ectiveness of the MSR system to continually recycle the
oxidized methionine residues. We assume that the e⁄ciency
of the MSR system in the substantia nigra of healthy vs.
Parkinsonian brains may di¡er. Of potential relevance in
this regard is a recent report indicating a decline in the activity
levels of MSR in various regions of the brains of Alzheimer’s
patients [57]. Thus, impaired MSR function may represent an
additional risk factor favoring the development of PD.
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